Atle Fund Management AB
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 5, 2025), Atle Fund Management AB reported 37 stock positions worth $226.5 million. Its top holding was Eli Lilly (LLY) at 12.6% of the portfolio, followed by Abbvie (ABBV, 8.3%) and Unitedhealth (UNH, 6.0%). Compared with Q4 2024, it opened 5 new positions, sold out of 4, added to 10 and reduced 19. The biggest buy was a new position in Gilead Sciences (GILD) and the biggest sale an exit from Intra-Cellular Therapies (ITCI).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $226.5M (Q1 2025)
- SEC Filing
- 0001381843-25-000004 ↗ filed May 5, 2025
Holdings Value
Holdings 37 stocks · $226.5M
| LLY Eli Lilly & Co. | 12.62% | 34,602 | $28.6M | Reduce -6.7% |
| ABBV Abbvie Inc. | 8.25% | 89,227 | $18.7M | Reduce -1.6% |
| UNH Unitedhealth Group Inc. | 5.96% | 25,782 | $13.5M | Reduce -26.8% |
| BSX Boston Scientific Corp. | 5.89% | 132,273 | $13.3M | Reduce -14.2% |
| MRK Merck & Co. Inc. | 5.06% | 127,679 | $11.5M | Add +20.8% |
| TMO Thermo Fisher Scientific Inc. | 5.02% | 22,857 | $11.4M | Reduce -8.2% |
| VRTX Vertex Pharmaceuticals Inc. | 4.88% | 22,808 | $11.1M | Add +2.5% |
| COR Cencora Inc. | 3.87% | 31,553 | $8.8M | Reduce -3.1% |
| GILD Gilead Sciences Inc. | 3.81% | 76,998 | $8.6M | New |
| SYK Stryker Corp. | 3.78% | 22,998 | $8.6M | Reduce -10.4% |
| NBIX Neurocrine Biosciences Inc. | 3.71% | 75,881 | $8.4M | Add +12.0% |
| AMGN Amgen Inc. | 3.66% | 26,577 | $8.3M | Reduce -3.0% |
| ISRG Intuitive Surgical Inc. | 3.36% | 15,345 | $7.6M | New |
| ALKS Alkermes PLC | 3.13% | 214,778 | $7.1M | Reduce -19.4% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 3.02% | 25,141 | $6.8M | Add +130.7% |
| BBIO Bridgebio Pharma Inc. | 2.31% | 151,348 | $5.2M | Add +46.9% |
| EW Edwards Lifesciences Corp. | 1.91% | 59,696 | $4.3M | Reduce -12.6% |
| UFPT Ufp Technologies Inc. | 1.89% | 21,259 | $4.3M | Reduce -8.2% |
| KRYS Krystal Biotech Inc. | 1.87% | 23,491 | $4.2M | Add +155.3% |
| CAH Cardinal Health Inc. | 1.68% | 27,688 | $3.8M | Reduce -9.8% |
| MIRM Mirum Pharmaceuticals Inc. | 1.54% | 77,263 | $3.5M | Reduce -33.8% |
| DXCM Dexcom Inc. | 1.38% | 45,841 | $3.1M | Reduce -23.7% |
| HRMY Harmony Biosciences Holdings | 1.34% | 91,301 | $3.0M | Reduce -24.2% |
| ACLX Arcellx Inc. | 1.28% | 44,171 | $2.9M | Add +5.0% |
| SLNO Soleno Therapeutics Inc. | 1.17% | 37,098 | $2.7M | Add +19.9% |
| NAMS Newamsterdam Pharma Co. NV | 0.97% | 107,783 | $2.2M | Reduce -22.4% |
| VRNA Verona Pharma Ltd. | 0.97% | 34,690 | $2.2M | New |
| IRTC Irhythm Holdings Inc. | 0.95% | 20,547 | $2.2M | New |
| SMMT Summit Therapeutics Inc. | 0.89% | 105,077 | $2.0M | Add +3.9% |
| RVMD Revolution Medicines Inc. | 0.86% | 54,961 | $1.9M | Reduce -11.6% |
| BCAX Bicara Therapeutics Inc. | 0.69% | 119,833 | $1.6M | New |
| MRUS Merus NV | 0.66% | 35,292 | $1.5M | Reduce -43.5% |
| JANX Janux Therapeutics Inc. | 0.56% | 46,808 | $1.3M | Add +18.3% |
| MREO Mereo Biopharma Group PL-ADR | 0.39% | 390,000 | $878K | No change |
| AUTL Autolus Therapeutics PLC | 0.33% | 479,644 | $743K | No change |
| CRBP Corbus Pharmaceuticals Holdi | 0.23% | 98,304 | $522K | No change |
| CABA Cabaletta Bio Inc. | 0.11% | 182,354 | $253K | Reduce -26.3% |
Portfolio Sells Q4 2024 → Q1 2025
| ITCI Intra-Cellular Therapies Inc. | Sold out | 0.00% | −2.82 |
| UNH Unitedhealth Group Inc. | Reduce -26.8% | 5.96% | −2.52 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −1.46 |
| TMO Thermo Fisher Scientific Inc. | Reduce -8.2% | 5.02% | −1.10 |
| LLY Eli Lilly & Co. | Reduce -6.7% | 12.62% | −0.99 |
| DXCM Dexcom Inc. | Reduce -23.7% | 1.38% | −0.84 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -33.8% | 1.54% | −0.74 |
| NAMS Newamsterdam Pharma Co. NV | Reduce -22.4% | 0.97% | −0.71 |
| BSX Boston Scientific Corp. | Reduce -14.2% | 5.89% | −0.67 |
| SYK Stryker Corp. | Reduce -10.4% | 3.78% | −0.63 |
| HRMY Harmony Biosciences Holdings | Reduce -24.2% | 1.34% | −0.61 |
| MRUS Merus NV | Reduce -43.5% | 0.66% | −0.59 |
| ALKS Alkermes PLC | Reduce -19.4% | 3.13% | −0.51 |
| EW Edwards Lifesciences Corp. | Reduce -12.6% | 1.91% | −0.49 |
| RVMD Revolution Medicines Inc. | Reduce -11.6% | 0.86% | −0.41 |
| MERSANA THERAPEUTICS INC | Sold out | 0.00% | −0.36 |
| PHVS Pharvaris NV | Sold out | 0.00% | −0.31 |
| CABA Cabaletta Bio Inc. | Reduce -26.3% | 0.11% | −0.15 |
| CAH Cardinal Health Inc. | Reduce -9.8% | 1.68% | −0.03 |
| AMGN Amgen Inc. | Reduce -3.0% | 3.66% | +0.28 |
| UFPT Ufp Technologies Inc. | Reduce -8.2% | 1.89% | +0.39 |
| COR Cencora Inc. | Reduce -3.1% | 3.87% | +0.40 |
| ABBV Abbvie Inc. | Reduce -1.6% | 8.25% | +0.67 |
Portfolio Buys Q4 2024 → Q1 2025
| GILD Gilead Sciences Inc. | New | 3.81% | +3.81 |
| ISRG Intuitive Surgical Inc. | New | 3.36% | +3.36 |
| ONC Beone Medicines Ltd.-ADR | Add +130.7% | 3.02% | +2.07 |
| VRTX Vertex Pharmaceuticals Inc. | Add +2.5% | 4.88% | +1.28 |
| KRYS Krystal Biotech Inc. | Add +155.3% | 1.87% | +1.17 |
| BBIO Bridgebio Pharma Inc. | Add +46.9% | 2.31% | +0.97 |
| VRNA Verona Pharma Ltd. | New | 0.97% | +0.97 |
| IRTC Irhythm Holdings Inc. | New | 0.95% | +0.95 |
| SLNO Soleno Therapeutics Inc. | Add +19.9% | 1.17% | +0.70 |
| BCAX Bicara Therapeutics Inc. | New | 0.69% | +0.69 |
| SMMT Summit Therapeutics Inc. | Add +3.9% | 0.89% | +0.27 |
| MRK Merck & Co. Inc. | Add +20.8% | 5.06% | +0.13 |
| ACLX Arcellx Inc. | Add +5.0% | 1.28% | −0.28 |
| JANX Janux Therapeutics Inc. | Add +18.3% | 0.56% | −0.43 |
| NBIX Neurocrine Biosciences Inc. | Add +12.0% | 3.71% | −0.70 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |